Protagonist Therapeutics, Inc Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Protagonist Therapeutics, Inc (PTGX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $26.28 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-02-25
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $26.21, a 32.86% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $39.04, a 177.27% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2021-03-31 was $14.08, a 18.82% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-03-31 was $11.85, a 5.05% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $26.28, a 4.68% decline from fiscal 2024.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $27.57, a 17.42% increase from fiscal 2023.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $23.48, a 0.68% decline from fiscal 2022.
- Protagonist Therapeutics, Inc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $23.64, a 32.51% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $26.28 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $27.57 10-K · filed 2025-02-21 | |||
| 2023-12-31 | $23.48 10-K · filed 2024-02-27 | |||
| 2023-06-30 | $26.14 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $26.21 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $23.64 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $22.25 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $23.42 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $39.04 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $17.84 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $16.60 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $16.66 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $14.08 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $11.54 10-K · filed 2021-03-10 | |||
| 2020-09-30 | $11.88 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $10.88 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $11.85 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $14.08 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $13.30 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $12.27 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $12.48 10-Q · filed 2019-05-08 | |||
| 2018-09-30 | $14.99 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $15.76 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $20.12 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |